Table 2.
Response to rituximab treatment, overall and in subgroups
| Group | No. (%) | Responders, no. | % response (95% CI) | P* |
|---|---|---|---|---|
| All | 36 (100) | 11 | 31 (16-48) | — |
| Primary | 30 (83) | 7 | 23 (10-42) | .06 |
| Evans | 6 (17) | 4 | 67 (22-97) | |
| Male | 21 (58) | 4 | 19 (5-42) | .14 |
| Female | 15 (42) | 7 | 47 (21-73) | |
| White | 28 (78) | 8 | 29 (13-49) | .09 |
| Black | 4 (11) | 3 | 75 (19-99) | |
| Other | 4 (11) | 0 | 0 (0-60) | |
| Hispanic/Latino | 6 (17) | 1 | 17 (1-64) | .64 |
| Not Hispanic/Latino | 30 (83) | 10 | 33 (17-53) | |
| Refractory | 27 (75) | 8 | 30 (14-50) | > .99 |
| Not refractory | 9 (25) | 3 | 33 (7-70) | |
| Splenectomy | 7 (19) | 3 | 43 (10-82) | .65 |
| No splenectomy | 29 (81) | 8 | 28 (13-47) | |
| Steroid responsive† | 27 (75) | 11 | 41 (22-61) | .27 |
| Steroid nonresponsive | 4 (11) | 0 | 0 (0-60) | |
| Steroid unknown‡ | 5 (14) | — | — | |
| IVIG responsive† | 28 (78) | 9 | 32 (16-52) | > .99 |
| IVIG nonresponsive | 5 (14) | 2 | 40 (5-85) | |
| IVIG unknown‡ | 3 (8) | — | — | |
| Anti-D responsive† | 21 (58) | 4 | 19 (5-42) | .59 |
| Anti-D nonresponsive | 6 (17) | 2 | 33 (4-78) | |
| Anti-D unknown‡ | 9 (25) | — | — |
— indicates not applicable.
*
Testing equal response in subgroups by the Fisher exact test.
†
From medical history prior to study.
‡
Not administered or response unknown.